MedTrace Logo

Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer

NCT00380874 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-02-11

Study results available
· View outcomes & findings →

Summary

Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral neuropathy.

Conditions

  • Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG

Pregabalin

150- 600 mg/day (double blind in divided doses)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Australia
  • Germany
  • Italy
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380874 on ClinicalTrials.gov